首页> 外文期刊>Journal of Clinical Bioinformatics >A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer
【24h】

A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer

机译:从微阵列数据,疾病基因和相互作用组网络预测药物靶标的网络流方法-前列腺癌案例研究

获取原文
           

摘要

Background Systematic approach for drug discovery is an emerging discipline in systems biology research area. It aims at integrating interaction data and experimental data to elucidate diseases and also raises new issues in drug discovery for cancer treatment. However, drug target discovery is still at a trial-and-error experimental stage and it is a challenging task to develop a prediction model that can systematically detect possible drug targets to deal with complex diseases. Methods We integrate gene expression, disease genes and interaction networks to identify the effective drug targets which have a strong influence on disease genes using network flow approach. In the experiments, we adopt the microarray dataset containing 62 prostate cancer samples and 41 normal samples, 108 known prostate cancer genes and 322 approved drug targets treated in human extracted from DrugBank database to be candidate proteins as our test data. Using our method, we prioritize the candidate proteins and validate them to the known prostate cancer drug targets. Results We successfully identify potential drug targets which are strongly related to the well known drugs for prostate cancer treatment and also discover more potential drug targets which raise the attention to biologists at present. We denote that it is hard to discover drug targets based only on differential expression changes due to the fact that those genes used to be drug targets may not always have significant expression changes. Comparing to previous methods that depend on the network topology attributes, they turn out that the genes having potential as drug targets are weakly correlated to critical points in a network. In comparison with previous methods, our results have highest mean average precision and also rank the position of the truly drug targets higher. It thereby verifies the effectiveness of our method. Conclusions Our method does not know the real ideal routes in the disease network but it tries to find the feasible flow to give a strong influence to the disease genes through possible paths. We successfully formulate the identification of drug target prediction as a maximum flow problem on biological networks and discover potential drug targets in an accurate manner.
机译:背景技术用于药物发现的系统方法是系统生物学研究领域中的新兴学科。它旨在整合相互作用数据和实验数据以阐明疾病,并在用于癌症治疗的药物发现中提出新问题。然而,药物靶标的发现仍处于试验和试验阶段,开发能够系统检测可能的药物靶标以应对复杂疾病的预测模型是一项艰巨的任务。方法我们将基因表达,疾病基因和相互作用网络整合在一起,以使用网络流方法确定对疾病基因有重要影响的有效药物靶标。在实验中,我们采用包含来自62个前列腺癌样品和41个正常样品,108个已知前列腺癌基因和322个已批准药物靶标的微阵列数据集作为候选蛋白质,这些药物是从DrugBank数据库中提取的人作为治疗数据。使用我们的方法,我们对候选蛋白进行了优先排序,并将其验证为已知的前列腺癌药物靶标。结果我们成功地确定了与众所周知的前列腺癌治疗药物密切相关的潜在药物靶标,并发现了更多潜在的药物靶标,目前引起生物学家的关注。我们表示很难发现仅基于差异表达变化的药物靶标,原因是那些曾经用作药物靶标的基因可能并不总是具有明显的表达变化。与以前的依赖于网络拓扑属性的方法相比,他们发现具有作为药物靶标潜能的基因与网络中的关键点之间存在弱关联。与以前的方法相比,我们的结果具有最高的平均平均精度,并且还使真正的药物靶标的位置更高。从而验证了我们方法的有效性。结论我们的方法不知道疾病网络中真正的理想途径,但是它试图找到可行的流程以通过可能的途径对疾病基因产生强大的影响。我们成功地将识别出的药物目标预测公式化为生物网络上的最大流量问题,并以准确的方式发现潜在的药物目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号